Ganitumab

• CAT Number: I042420
• CAS Number: 905703-97-1
• Purity: ≥95%

Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer[1].
Ganitumab (AMG 479; 0.032-500 nM; 10 min; CT26 cells) binds mIGF1R and inhibits IGF1- and IGF2-mediated activation of mIGF1R[1].
Ganitumab (AMG 479; 1 mg/dose; i.p; Naïve and tumor-bearing mice) inhibits IGF1-induced activation of mIGF1R in murine lungs[1].
Ganitumab (300 μg/dose; i.p.; female athymic nude mice) reduces peripheral blood neutrophils[1].
Ganitumab (300 μg/dose; i.p.; male athymic nude mice) causes impaired glucose tolerance in male mice and increases serum levels of mGH, mIGF1 and mIGFBP3[1].

Reference

[1]. Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55.
 [Content Brief]